The Role of PDTs in Clinical Practice
Panelists discuss how prescription digital therapeutics are currently used in clinical practice, noting that while none are yet approved for schizophrenia, CT-155 shows promise in phase 3 trials, and existing PDTs like Rejoyn for depression demonstrate the potential for technology-based interventions.
Currently, patients with schizophrenia do not have access to FDA-approved prescription digital therapeutics, though promising developments are emerging.
One digital therapeutic (CT-155) has received breakthrough designation and completed phase 3 clinical trials, with results expected to be presented to the mental health community soon.
For patients with depression, clinicians can prescribe reSET, an approved digital therapeutic that provides cognitive behavioral therapy as an adjunct to medications, demonstrating the potential for similar applications in schizophrenia treatment.
Clinical experience with existing PDTs reveals both opportunities and challenges for patient care.
Prescription digital therapeutics demonstrate potential for technology-based interventions.
Author summary: PDTs show promise in clinical practice for schizophrenia and depression treatment.
More News
- City elects to renovate and expand hours of Farmers' Market washroom
- As top LDS Church leaders age, they move closer to ‘the zone of dementia’
- Apple says US passport digital IDs are coming to Wallet 'soon' | TechCrunch
- Waymo Co-CEO Tekedra Mawakana on What’s Next: Highways, Airports, New Cities
- Park Washroom Enhancement Program
- Opinion: Get Waymos off our streets - Washington Square News